Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crinò L. Cappuzzo F, et al. Among authors: papi m. Lung Cancer. 2006 Jun;52(3):319-25. doi: 10.1016/j.lungcan.2006.03.004. Epub 2006 Apr 19. Lung Cancer. 2006. PMID: 16630670 Clinical Trial.
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer). Santo A, et al. Among authors: papi m. Lung Cancer. 2019 Aug;134:121-126. doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11. Lung Cancer. 2019. PMID: 31319970 Clinical Trial.
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Dazzi C, Cariello A, Casanova C, Verlicchi A, Montanari M, Papiani G, Freier E, Mazza V, Milandri C, Gamboni A, Papi M, Leoni M, Cruciani G, Vertogen B. Dazzi C, et al. Among authors: papi m. Clin Lung Cancer. 2013 Jan;14(1):28-33. doi: 10.1016/j.cllc.2012.03.003. Epub 2012 Apr 25. Clin Lung Cancer. 2013. PMID: 22537509 Clinical Trial.
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Ulivi P, et al. Among authors: papi m. Clin Lung Cancer. 2016 Sep;17(5):384-390. doi: 10.1016/j.cllc.2015.11.004. Epub 2015 Dec 1. Clin Lung Cancer. 2016. PMID: 26712101
[Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].
Tassinari D, Genestreti G, Pasquini E, Fantini M, Poggi B, Tamburini E, Papi M, Ioli G, Oliverio G, Fochessati F, Arcangeli V, Agostini V, Mianulli AM, Imola M, Fattori PP, Ravaioli A. Tassinari D, et al. Among authors: papi m. Recenti Prog Med. 2005 May;96(5):234-9. Recenti Prog Med. 2005. PMID: 15977652 Italian.
Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial.
Tassinari D, Fochessati F, Arcangeli V, Sartori S, Agostini V, Fantini M, Genestreti G, Grassia S, Ioli G, Imola M, Iorio D, Mianulli AM, Monticelli G, Oliverio G, Panzini I, Papi M, Poggi B, Polselli A, Pulini S, Tamburini E, Fattori PP, Ravaioli A. Tassinari D, et al. Among authors: papi m. Tumori. 2004 Jan-Feb;90(1):54-9. doi: 10.1177/030089160409000113. Tumori. 2004. PMID: 15143973 Clinical Trial.
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P. Canale M, et al. Among authors: papi m. Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780855
255 results